JP6474082B2 - 眼疾患および眼障害の治療のためのヒト単球亜集団 - Google Patents

眼疾患および眼障害の治療のためのヒト単球亜集団 Download PDF

Info

Publication number
JP6474082B2
JP6474082B2 JP2016514532A JP2016514532A JP6474082B2 JP 6474082 B2 JP6474082 B2 JP 6474082B2 JP 2016514532 A JP2016514532 A JP 2016514532A JP 2016514532 A JP2016514532 A JP 2016514532A JP 6474082 B2 JP6474082 B2 JP 6474082B2
Authority
JP
Japan
Prior art keywords
cells
pbmc
monocyte
cell
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016514532A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522830A5 (https=
JP2016522830A (ja
Inventor
アイゼンバッハ‐シュワルツ、ミハエル
ヨレス、エスター
バー‐オン、インバル ベンハー
バー‐オン、インバル ベンハー
Original Assignee
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イエダ リサーチ アンド ディベロップメント カンパニー リミテッド, イエダ リサーチ アンド ディベロップメント カンパニー リミテッド filed Critical イエダ リサーチ アンド ディベロップメント カンパニー リミテッド
Publication of JP2016522830A publication Critical patent/JP2016522830A/ja
Publication of JP2016522830A5 publication Critical patent/JP2016522830A5/ja
Application granted granted Critical
Publication of JP6474082B2 publication Critical patent/JP6474082B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2016514532A 2013-05-22 2014-05-22 眼疾患および眼障害の治療のためのヒト単球亜集団 Expired - Fee Related JP6474082B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361826159P 2013-05-22 2013-05-22
US61/826,159 2013-05-22
US201361915069P 2013-12-12 2013-12-12
US61/915,069 2013-12-12
PCT/IL2014/050463 WO2014188436A1 (en) 2013-05-22 2014-05-22 Human monocyte sub-population for treatment of eye diseases and disorders

Publications (3)

Publication Number Publication Date
JP2016522830A JP2016522830A (ja) 2016-08-04
JP2016522830A5 JP2016522830A5 (https=) 2017-06-29
JP6474082B2 true JP6474082B2 (ja) 2019-02-27

Family

ID=51933057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016514532A Expired - Fee Related JP6474082B2 (ja) 2013-05-22 2014-05-22 眼疾患および眼障害の治療のためのヒト単球亜集団

Country Status (11)

Country Link
US (1) US10188679B2 (https=)
EP (1) EP2999479B1 (https=)
JP (1) JP6474082B2 (https=)
KR (1) KR102257163B1 (https=)
CN (1) CN105377273A (https=)
AU (1) AU2014269935B2 (https=)
BR (1) BR112015029299A2 (https=)
CA (1) CA2913274C (https=)
IL (1) IL242694B (https=)
MX (1) MX2015016062A (https=)
WO (1) WO2014188436A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2790712B1 (en) * 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury
KR20260003355A (ko) 2015-09-08 2026-01-06 후지필름 셀룰러 다이내믹스, 인코포레이티드 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제
DE102017125335B4 (de) * 2017-10-27 2019-10-17 Epiontis Gmbh Amplikon-Region als epigenetischer Marker zur Identifizierung von Immunzellen, insbesondere nicht-klassischer Monozyten
KR102228401B1 (ko) * 2018-07-05 2021-03-16 고려대학교 산학협력단 유리체 절제술 및 안구 내 mnu 주입과 제거를 이용한 망막 변성 동물 모델의 제조방법 및 이를 이용한 망막 변성 동물 모델
BR112022011339A2 (pt) * 2019-12-11 2022-10-04 Myeloid Therapeutics Inc Composições de células terapêuticas e métodos para fabricação e usos das mesmas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267955B1 (en) 1995-09-15 2001-07-31 Yeda Research And Development Co. Ltd. Mononuclear phagocytes and their use to promote axonal regeneration
US5800812A (en) 1995-09-15 1998-09-01 Yeda Research And Development Co. Ltd. Methods of use of mononuclear phagocytes to promote axonal regeneration
AU2002353465B2 (en) 2001-11-21 2008-10-16 Yeda Research And Development Co. Ltd. Process for the manufacture of human mononuclear phagocytic leukocytes
CA2598029A1 (en) * 2005-02-24 2006-10-05 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
CA2752679A1 (en) 2009-02-20 2010-08-26 The Scripps Research Institute Isolated monocyte populations and related therapeutic applications
EP2790712B1 (en) 2011-12-14 2016-08-31 Yeda Research and Development Co. Ltd. Human monocyte sub-population for treatment of central nervous system injury

Also Published As

Publication number Publication date
US10188679B2 (en) 2019-01-29
EP2999479A4 (en) 2017-02-22
BR112015029299A2 (pt) 2017-07-25
WO2014188436A1 (en) 2014-11-27
CN105377273A (zh) 2016-03-02
CA2913274C (en) 2021-10-12
KR20160016874A (ko) 2016-02-15
EP2999479B1 (en) 2021-01-06
AU2014269935A1 (en) 2016-01-21
US20160166612A1 (en) 2016-06-16
MX2015016062A (es) 2016-08-03
AU2014269935B2 (en) 2019-01-24
EP2999479A1 (en) 2016-03-30
JP2016522830A (ja) 2016-08-04
CA2913274A1 (en) 2014-11-27
KR102257163B1 (ko) 2021-05-27
IL242694B (en) 2021-01-31

Similar Documents

Publication Publication Date Title
Forrester et al. Dendritic cell physiology and function in the eye
Evans et al. Protective and regenerative roles of T cells in central nervous system disorders
Niederkorn Immune privilege in the anterior chamber of the eye
US7560102B2 (en) Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease
Dando et al. A case of mistaken identity: CD11c‐eYFP+ cells in the normal mouse brain parenchyma and neural retina display the phenotype of microglia, not dendritic cells
JP6474082B2 (ja) 眼疾患および眼障害の治療のためのヒト単球亜集団
JP4434729B2 (ja) 神経保護治療法のためのポリ−Ｇｌｕ，Ｔｙｒとこれで処理したＴ細胞の使用
Benhar et al. The retinal pigment epithelium as a gateway for monocyte trafficking into the eye
EP2046366B1 (en) Copolymer-1 for treatment of age-related macular degeneration
Vu et al. CD4+ T-cell responses mediate progressive neurodegeneration in experimental ischemic retinopathy
AU2004275682B2 (en) Novel use of antisecretory factor
Kwidzinski et al. Self-tolerance in the immune privileged CNS: lessons from the entorhinal cortex lesion model
Schwartz Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders
JP7738377B2 (ja) 神経炎症の調節
Adamus et al. Systemic immunotherapy delays photoreceptor cell loss and prevents vascular pathology in Royal College of Surgeons rats
JP2025118706A (ja) Ｂ細胞免疫療法
US20040248802A1 (en) Poly-Glu, Tyr for neuroprotective therapy
Ng et al. In Vitro–Generated Autoimmune Regulatory T Cells Enhance Intravitreous Allogeneic Retinal Graft Survival
US12508285B2 (en) Oligodendrocyte-derived extracellular vesicles for therapy of multiple sclerosis
MachaliNska et al. Research Article Neuroprotective and Antiapoptotic Activity of Lineage-Negative Bone Marrow Cells after Intravitreal Injection in a Mouse Model of Acute Retinal Injury
Schwartz Immune-Based Cell Therapy for Acute and Chronic Neurodegeneratlve Disorders
HK1127858B (en) Copolymer-1 for treatment of age-related macular degeneration

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160120

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180629

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190123

R150 Certificate of patent or registration of utility model

Ref document number: 6474082

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees